Therapeutic approach to Sars-COV-2 in early treatment of patient not-hospitalized: a case report

Background: Sars-CoV-2 induces a massive inflammatory response mediated by macrophages, activated thanks to IFNγ secreted by T lymphocytes. Viral Spanish influenza has been reported that h could have the similar inflammatory mechanism that we can observe in COVID-19 patients 16). We tested this theory on a 55-year-old male patient, Sars-COV-2 positive. Case presentation: We treated our patient using clinical data and therapeutic approaches from a team of Chinese researchers, established during the beginning of the epidemic in December 2019. The new member of the human coronavirus, officially called SARS - CoV - 2 (severe acute respiratory syndrome coronavirus 2) by the International Committee on Taxonomy of Viruses (ICTV) is a new RNA virus strain that has not been previously identified in humans (1). This patient showed a Sars Cov-2 infection and was treated early with glucocorticoids. The patient immediately showed a regression of fever and an improvement of symptoms. Conclusions: We hypothesize that the initial stages of the infection can be treated with glucocorticoid therapy.